BET inhibitors, a class of drugs already in clinical trials, might work especially well in breast cancer patients who have acquired a Y537S mutation, according to a preclinical study led by researchers at UT Southwestern Medical Center.
Breast cancer surgeon Tari A. King was appointed as chief surgical officer for the cancer service line at Winship Cancer Institute of Emory University and Emory Healthcare. Joining Emory on July 14, she will also be the chief of the newly formed Division of Breast Surgery in the Department of Surgery at Emory University School of Medicine and co-director of Winship’s Glenn Family Breast Center.
